FDA Approved: BRINEURA — Supplemental Application (BioMarin Pharmaceutical Inc.)

View source ↗

Summary

The FDA approved a supplemental application for BRINEURA (cerliponase alfa) submitted by BioMarin Pharmaceutical Inc. for use in CLN2 disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infantile Neuronal Ceroid Lipofuscinosis Type 2

Drugs mentioned

• BRINEURA (cerliponase alfa)

Snippet

SUPPL AP for BRINEURA (CERLIPONASE ALFA)